Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Selective Modulation of A1 Astrocytes by Drug-Loaded Nano-Structured Gel in Spinal Cord Injury.

Vismara I, Papa S, Veneruso V, Mauri E, Mariani A, De Paola M, Affatato R, Rossetti A, Sponchioni M, Moscatelli D, Sacchetti A, Rossi F, Forloni G, Veglianese P.

ACS Nano. 2020 Jan 28;14(1):360-371. doi: 10.1021/acsnano.9b05579. Epub 2019 Dec 30.

PMID:
31887011
2.

How can nanovectors be used to treat spinal cord injury?

Rossi F, Papa S, Perale G, Veglianese P.

Nanomedicine (Lond). 2019 Dec;14(24):3123-3125. doi: 10.2217/nnm-2019-0355. No abstract available.

3.

Effects of primary amine-based coatings on microglia internalization of nanogels.

Mauri E, Veglianese P, Papa S, Rossetti A, De Paola M, Mariani A, Posel Z, Posocco P, Sacchetti A, Rossi F.

Colloids Surf B Biointerfaces. 2020 Jan 1;185:110574. doi: 10.1016/j.colsurfb.2019.110574. Epub 2019 Oct 17.

PMID:
31704605
4.

A refinement approach in a mouse model of rehabilitation research. Analgesia strategy, reduction approach and infrared thermography in spinal cord injury.

Redaelli V, Papa S, Marsella G, Grignaschi G, Bosi A, Ludwig N, Luzi F, Vismara I, Rimondo S, Veglianese P, Tepteva S, Mazzola S, Zerbi P, Porcu L, Roughan JV, Parati G, Calvillo L.

PLoS One. 2019 Oct 30;14(10):e0224337. doi: 10.1371/journal.pone.0224337. eCollection 2019.

5.

Stem cell paracrine effect and delivery strategies for spinal cord injury regeneration.

Veneruso V, Rossi F, Villella A, Bena A, Forloni G, Veglianese P.

J Control Release. 2019 Apr 28;300:141-153. doi: 10.1016/j.jconrel.2019.02.038. Epub 2019 Mar 6. Review.

PMID:
30851286
6.

Nanovector-Mediated Drug Delivery in Spinal Cord Injury: A Multitarget Approach.

Papa S, Rossi F, Vismara I, Forloni G, Veglianese P.

ACS Chem Neurosci. 2019 Mar 20;10(3):1173-1182. doi: 10.1021/acschemneuro.8b00700. Epub 2019 Feb 25. Review.

PMID:
30763071
7.

Profiling of orthosteric and allosteric group-III metabotropic glutamate receptor ligands on various G protein-coupled receptors with Tag-lite® assays.

Belhocine A, Veglianese P, Hounsou C, Dupuis E, Acher F, Durroux T, Goudet C, Pin JP.

Neuropharmacology. 2018 Sep 15;140:233-245. doi: 10.1016/j.neuropharm.2018.07.032. Epub 2018 Aug 9.

PMID:
30099051
8.

Mesenchymal stem cells encapsulated into biomimetic hydrogel scaffold gradually release CCL2 chemokine in situ preserving cytoarchitecture and promoting functional recovery in spinal cord injury.

Papa S, Vismara I, Mariani A, Barilani M, Rimondo S, De Paola M, Panini N, Erba E, Mauri E, Rossi F, Forloni G, Lazzari L, Veglianese P.

J Control Release. 2018 May 28;278:49-56. doi: 10.1016/j.jconrel.2018.03.034. Epub 2018 Apr 3.

PMID:
29621597
9.

Microwave-assisted synthesis of TEMPO-labeled hydrogels traceable with MRI.

Mauri E, Micotti E, Rossetti A, Melone L, Papa S, Azzolini G, Rimondo S, Veglianese P, Punta C, Rossi F, Sacchetti A.

Soft Matter. 2018 Jan 24;14(4):558-565. doi: 10.1039/c7sm02292a.

PMID:
29333553
10.

Amyotrophic Lateral Sclerosis, a Multisystem Pathology: Insights into the Role of TNFα.

Tortarolo M, Lo Coco D, Veglianese P, Vallarola A, Giordana MT, Marcon G, Beghi E, Poloni M, Strong MJ, Iyer AM, Aronica E, Bendotti C.

Mediators Inflamm. 2017;2017:2985051. doi: 10.1155/2017/2985051. Epub 2017 Sep 10. Review.

11.

Current Options for Cell Therapy in Spinal Cord Injury.

Vismara I, Papa S, Rossi F, Forloni G, Veglianese P.

Trends Mol Med. 2017 Sep;23(9):831-849. doi: 10.1016/j.molmed.2017.07.005. Epub 2017 Aug 12. Review.

PMID:
28811172
12.

Novel functionalization strategies to improve drug delivery from polymers.

Mauri E, Papa S, Masi M, Veglianese P, Rossi F.

Expert Opin Drug Deliv. 2017 Nov;14(11):1305-1313. doi: 10.1080/17425247.2017.1285280. Epub 2017 Jan 30. Review.

PMID:
28103740
13.

3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors.

Giordano S, Morosi L, Veglianese P, Licandro SA, Frapolli R, Zucchetti M, Cappelletti G, Falciola L, Pifferi V, Visentin S, D'Incalci M, Davoli E.

Sci Rep. 2016 Nov 14;6:37027. doi: 10.1038/srep37027.

14.

Modulators of microglia: a patent review.

Papa S, Caron I, Rossi F, Veglianese P.

Expert Opin Ther Pat. 2016;26(4):427-37. doi: 10.1517/13543776.2016.1135901. Epub 2016 Mar 16. Review.

PMID:
26726838
15.

Non-invasive in vitro and in vivo monitoring of degradation of fluorescently labeled hyaluronan hydrogels for tissue engineering applications.

Zhang Y, Rossi F, Papa S, Violatto MB, Bigini P, Sorbona M, Redaelli F, Veglianese P, Hilborn J, Ossipov DA.

Acta Biomater. 2016 Jan;30:188-198. doi: 10.1016/j.actbio.2015.11.053. Epub 2015 Nov 24.

PMID:
26621694
16.

A new three dimensional biomimetic hydrogel to deliver factors secreted by human mesenchymal stem cells in spinal cord injury.

Caron I, Rossi F, Papa S, Aloe R, Sculco M, Mauri E, Sacchetti A, Erba E, Panini N, Parazzi V, Barilani M, Forloni G, Perale G, Lazzari L, Veglianese P.

Biomaterials. 2016 Jan;75:135-147. doi: 10.1016/j.biomaterials.2015.10.024. Epub 2015 Oct 22.

PMID:
26497428
17.

Early modulation of pro-inflammatory microglia by minocycline loaded nanoparticles confers long lasting protection after spinal cord injury.

Papa S, Caron I, Erba E, Panini N, De Paola M, Mariani A, Colombo C, Ferrari R, Pozzer D, Zanier ER, Pischiutta F, Lucchetti J, Bassi A, Valentini G, Simonutti G, Rossi F, Moscatelli D, Forloni G, Veglianese P.

Biomaterials. 2016 Jan;75:13-24. doi: 10.1016/j.biomaterials.2015.10.015. Epub 2015 Oct 9.

PMID:
26474039
18.

Bone marrow mesenchymal stromal cells drive protective M2 microglia polarization after brain trauma.

Zanier ER, Pischiutta F, Riganti L, Marchesi F, Turola E, Fumagalli S, Perego C, Parotto E, Vinci P, Veglianese P, D'Amico G, Verderio C, De Simoni MG.

Neurotherapeutics. 2014 Jul;11(3):679-95. doi: 10.1007/s13311-014-0277-y.

19.

Ranolazine ameliorates postresuscitation electrical instability and myocardial dysfunction and improves survival with good neurologic recovery in a rat model of cardiac arrest.

Fumagalli F, Russo I, Staszewsky L, Li Y, Letizia T, Masson S, Novelli D, Rocchetti M, Canovi M, Veglianese P, Gobbi M, Latini R, Zaza A, Ristagno G.

Heart Rhythm. 2014 Sep;11(9):1641-7. doi: 10.1016/j.hrthm.2014.05.023. Epub 2014 May 22.

PMID:
24858811
20.

Nanovector-mediated drug delivery for spinal cord injury treatment.

Caron I, Papa S, Rossi F, Forloni G, Veglianese P.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014 Sep-Oct;6(5):506-15. doi: 10.1002/wnan.1276. Epub 2014 May 21. Review.

PMID:
24845580
21.

Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury.

Papa S, Ferrari R, De Paola M, Rossi F, Mariani A, Caron I, Sammali E, Peviani M, Dell'Oro V, Colombo C, Morbidelli M, Forloni G, Perale G, Moscatelli D, Veglianese P.

J Control Release. 2014 Jan 28;174:15-26. doi: 10.1016/j.jconrel.2013.11.001. Epub 2013 Nov 10.

PMID:
24225226
22.

Selective nanovector mediated treatment of activated proinflammatory microglia/macrophages in spinal cord injury.

Papa S, Rossi F, Ferrari R, Mariani A, De Paola M, Caron I, Fiordaliso F, Bisighini C, Sammali E, Colombo C, Gobbi M, Canovi M, Lucchetti J, Peviani M, Morbidelli M, Forloni G, Perale G, Moscatelli D, Veglianese P.

ACS Nano. 2013 Nov 26;7(11):9881-95. doi: 10.1021/nn4036014. Epub 2013 Oct 18.

PMID:
24138479
23.

Soluble Aβ oligomer-induced synaptopathy: c-Jun N-terminal kinase's role.

Sclip A, Arnaboldi A, Colombo I, Veglianese P, Colombo L, Messa M, Mancini S, Cimini S, Morelli F, Antoniou X, Welker E, Salmona M, Borsello T.

J Mol Cell Biol. 2013 Aug;5(4):277-9. doi: 10.1093/jmcb/mjt015. Epub 2013 Apr 18. No abstract available.

PMID:
23606726
24.

Tunable hydrogel-nanoparticles release system for sustained combination therapies in the spinal cord.

Rossi F, Ferrari R, Papa S, Moscatelli D, Casalini T, Forloni G, Perale G, Veglianese P.

Colloids Surf B Biointerfaces. 2013 Aug 1;108:169-77. doi: 10.1016/j.colsurfb.2013.02.046. Epub 2013 Mar 14.

PMID:
23537835
25.

Current options for drug delivery to the spinal cord.

Rossi F, Perale G, Papa S, Forloni G, Veglianese P.

Expert Opin Drug Deliv. 2013 Mar;10(3):385-96. doi: 10.1517/17425247.2013.751372. Epub 2013 Jan 6. Review.

PMID:
23289716
26.

Hydrogels in spinal cord injury repair strategies.

Perale G, Rossi F, Sundstrom E, Bacchiega S, Masi M, Forloni G, Veglianese P.

ACS Chem Neurosci. 2011 Jul 20;2(7):336-45. doi: 10.1021/cn200030w. Epub 2011 May 4. Review.

27.

Neuroprotective effects of toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration.

De Paola M, Mariani A, Bigini P, Peviani M, Ferrara G, Molteni M, Gemma S, Veglianese P, Castellaneta V, Boldrin V, Rossetti C, Chiabrando C, Forloni G, Mennini T, Fanelli R.

Mol Med. 2012 Sep 7;18:971-81. doi: 10.2119/molmed.2012.00020.

28.

The toxicity of a mutant prion protein is cell-autonomous, and can be suppressed by wild-type prion protein on adjacent cells.

Biasini E, Turnbaugh JA, Massignan T, Veglianese P, Forloni G, Bonetto V, Chiesa R, Harris DA.

PLoS One. 2012;7(3):e33472. doi: 10.1371/journal.pone.0033472. Epub 2012 Mar 12.

29.

Specific inhibition of the JNK pathway promotes locomotor recovery and neuroprotection after mouse spinal cord injury.

Repici M, Chen X, Morel MP, Doulazmi M, Sclip A, Cannaya V, Veglianese P, Kraftsik R, Mariani J, Borsello T, Dusart I.

Neurobiol Dis. 2012 Jun;46(3):710-21. doi: 10.1016/j.nbd.2012.03.014. Epub 2012 Mar 9.

PMID:
22426389
30.

Multiple drug delivery hydrogel system for spinal cord injury repair strategies.

Perale G, Rossi F, Santoro M, Peviani M, Papa S, Llupi D, Torriani P, Micotti E, Previdi S, Cervo L, Sundström E, Boccaccini AR, Masi M, Forloni G, Veglianese P.

J Control Release. 2012 Apr 30;159(2):271-80. doi: 10.1016/j.jconrel.2011.12.025. Epub 2011 Dec 29.

PMID:
22227024
31.

Sustained Delivery of Chondroitinase ABC from Hydrogel System.

Rossi F, Veglianese P, Santoro M, Papa S, Rogora C, Dell'Oro V, Forloni G, Masi M, Perale G.

J Funct Biomater. 2012 Mar 19;3(1):199-208. doi: 10.3390/jfb3010199.

32.

c-Jun N-terminal kinase regulates soluble Aβ oligomers and cognitive impairment in AD mouse model.

Sclip A, Antoniou X, Colombo A, Camici GG, Pozzi L, Cardinetti D, Feligioni M, Veglianese P, Bahlmann FH, Cervo L, Balducci C, Costa C, Tozzi A, Calabresi P, Forloni G, Borsello T.

J Biol Chem. 2011 Dec 23;286(51):43871-80. doi: 10.1074/jbc.M111.297515. Epub 2011 Oct 27.

33.

Intracerebroventricular administration of human umbilical cord blood cells delays disease progression in two murine models of motor neuron degeneration.

Bigini P, Veglianese P, Andriolo G, Cova L, Grignaschi G, Caron I, Daleno C, Barbera S, Ottolina A, Calzarossa C, Lazzari L, Mennini T, Bendotti C, Silani V.

Rejuvenation Res. 2011 Dec;14(6):623-39. doi: 10.1089/rej.2011.1197. Epub 2011 Oct 6.

PMID:
21978082
34.

Characterization and degradation behavior of agar-carbomer based hydrogels for drug delivery applications: solute effect.

Rossi F, Santoro M, Casalini T, Veglianese P, Masi M, Perale G.

Int J Mol Sci. 2011;12(6):3394-408. doi: 10.3390/ijms12063394. Epub 2011 May 25.

35.

A new fluorogenic peptide determines proteasome activity in single cells.

Urru SA, Veglianese P, De Luigi A, Fumagalli E, Erba E, Gonella Diaza R, Carrà A, Davoli E, Borsello T, Forloni G, Pengo N, Monzani E, Cascio P, Cenci S, Sitia R, Salmona M.

J Med Chem. 2010 Oct 28;53(20):7452-60. doi: 10.1021/jm100362x.

PMID:
20883027
36.

Mutant prion protein expression is associated with an alteration of the Rab GDP dissociation inhibitor alpha (GDI)/Rab11 pathway.

Massignan T, Biasini E, Lauranzano E, Veglianese P, Pignataro M, Fioriti L, Harris DA, Salmona M, Chiesa R, Bonetto V.

Mol Cell Proteomics. 2010 Apr;9(4):611-22. doi: 10.1074/mcp.M900271-MCP200. Epub 2009 Dec 7.

37.

Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis.

Cheroni C, Marino M, Tortarolo M, Veglianese P, De Biasi S, Fontana E, Zuccarello LV, Maynard CJ, Dantuma NP, Bendotti C.

Hum Mol Genet. 2009 Jan 1;18(1):82-96. doi: 10.1093/hmg/ddn319. Epub 2008 Sep 29.

38.

Distribution and cellular localization of high mobility group box protein 1 (HMGB1) in the spinal cord of a transgenic mouse model of ALS.

Lo Coco D, Veglianese P, Allievi E, Bendotti C.

Neurosci Lett. 2007 Jan 22;412(1):73-7. Epub 2006 Dec 15.

PMID:
17196331
39.

Inter- and intracellular signaling in amyotrophic lateral sclerosis: role of p38 mitogen-activated protein kinase.

Bendotti C, Bao Cutrona M, Cheroni C, Grignaschi G, Lo Coco D, Peviani M, Tortarolo M, Veglianese P, Zennaro E.

Neurodegener Dis. 2005;2(3-4):128-34. Review.

PMID:
16909017
40.

Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS.

Veglianese P, Lo Coco D, Bao Cutrona M, Magnoni R, Pennacchini D, Pozzi B, Gowing G, Julien JP, Tortarolo M, Bendotti C.

Mol Cell Neurosci. 2006 Feb;31(2):218-31. Epub 2005 Oct 10.

PMID:
16219474
41.

Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus.

Richichi C, Lin EJ, Stefanin D, Colella D, Ravizza T, Grignaschi G, Veglianese P, Sperk G, During MJ, Vezzani A.

J Neurosci. 2004 Mar 24;24(12):3051-9.

42.

Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression.

Tortarolo M, Veglianese P, Calvaresi N, Botturi A, Rossi C, Giorgini A, Migheli A, Bendotti C.

Mol Cell Neurosci. 2003 Jun;23(2):180-92.

PMID:
12812752

Supplemental Content

Loading ...
Support Center